<DOC>
	<DOCNO>NCT01053026</DOCNO>
	<brief_summary>The aim clinical trial ass impact vascular function test circulate biomarkers short-term ( 12-week ) low-to-median intensity exercise training ARBs treatment patient DM hypertension .</brief_summary>
	<brief_title>Evaluation Effects Exercise Training ARB DM Patients</brief_title>
	<detailed_description>Inclusion criterion : type II diabetic hypertensive patient age 30 70 year-old HbA1c ≤ 8.0 % systolic blood pressure ≥ 140 mmHg . Neither ACEI ARB administrate recent 6 month . None significant concomitant systemic disease active infection , malignancy , hepatic significant renal dysfunction time enrollment ( i.e . total bilirubin &gt; 3 mg/dl，ALT &gt; 2.5 time upper limit normal range creatinine &gt; 3 mg/dl hospital ) . Information regard smoking , hypertension , hyperlipidemia well history cardiovascular disease obtain subject . No medication modify study period . After enrollment , patient assess ( 1 ) olmesartan ( 20 mg per day , titration ) , ( 2 ) life modification/exercise train 12 week . Vascular function exercise capacity study , peripheral blood test perform baseline 12- week follow-up . Data collect mean ± SD show comparison group use 2-sample test chi-square analysis continuous categorical variable , respectively . Adjust HbA1c level adjust use simple adjustment method ( ANCOVA equivalent regression analysis ) data analysis . Changes baseline follow-up measurement assess paired test . The frequency adverse effect group also compare 2-sample test . A p value &lt; 0.05 define statistically significant .</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>patient diabetes mellitus hypertension age 3070 years，systolic blood pressure 140160 mmHg HbA1c ≤ 8 % , history ACEI ARB use within 6 month active cardiovascular disease severe hepatic renal dysfunction ( CRE ≥ 3 mg/dl，TBil ≥ 3 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Angiotensin receptor II antagonist</keyword>
</DOC>